体内无药物的杂交脂质体用于淋巴瘤化疗。

Chemotherapy with hybrid liposomes for lymphoma without drugs in vivo.

作者信息

Nagami Hideaki, Matsumoto Yoko, Ueoka Ryuichi

机构信息

Graduate Course of Applied Chemistry, Sojo University, Japan.

出版信息

Int J Pharm. 2006 Jun 6;315(1-2):167-72. doi: 10.1016/j.ijpharm.2006.02.012. Epub 2006 Mar 6.

DOI:10.1016/j.ijpharm.2006.02.012

PMID:16574356

Abstract

Hybrid liposomes composed of dimyristoylphosphatidylcholine (DMPC) and polyoxyethylene (n) dodecyl ether (C(12)(EO)(n), n=21 and 25) were prepared with the method of sonication. Clear solution of hybrid liposomes having hydrodynamic diameter of 80-100 nm could be maintained over 3 weeks. Hybrid liposomes induced apoptosis for human lymphoma (MOLT-4 and RAJI) cells in vitro. No toxicity was observed in the rats after intravenously injecting hybrid liposomes in vivo. We clearly demonstrated that a mouse model of lymphoma was established and prolonged survival was obtained in mice models of lymphoma after the treatment with hybrid liposomes without drugs in vivo. The results in this study should support the prolonged survival for patients with lymphoma in clinical applications.

摘要

采用超声处理法制备了由二肉豆蔻酰磷脂酰胆碱（DMPC）和聚氧乙烯（n）十二烷基醚（C(12)(EO)(n)，n = 21和25）组成的混合脂质体。具有80 - 100 nm流体动力学直径的混合脂质体透明溶液可维持3周以上。混合脂质体在体外可诱导人淋巴瘤（MOLT - 4和RAJI）细胞凋亡。在体内静脉注射混合脂质体后，大鼠未观察到毒性。我们清楚地证明，建立了淋巴瘤小鼠模型，并且在体内用不含药物的混合脂质体治疗后，淋巴瘤小鼠模型的生存期得以延长。本研究结果应能支持淋巴瘤患者在临床应用中的生存期延长。